Triomics has successfully raised $22 million in Series B funding to enhance its AI platform aimed at improving oncology data management and patient care.
The funding round, led by Battery Ventures, includes contributions from existing investors such as Nexus Venture Partners, Lightspeed, and Y Combinator, as well as new strategic partners like Oncology Ventures and Precision Health Informatics. This investment elevates Triomics' total funding to over $36 million, enabling the company to expand its AI capabilities within cancer centers and life sciences organizations. Triomics is already collaborating with prestigious institutions, including Memorial Sloan Kettering and MD Anderson.
Triomics addresses the significant challenge of information overload in oncology, where traditional systems struggle to manage vast amounts of clinical data. The platform utilizes AI to transform unstructured patient records into structured insights, facilitating better clinical workflows. Early results show promising outcomes, including a 40% increase in clinical trial matches and a 67% reduction in chart review times, demonstrating the platform's potential to streamline oncology practices.
As Triomics continues to integrate its AI technology into clinical trial operations, it aims to build a robust network that enhances both patient care and research capabilities. The company's focus on providing verifiable, source-backed insights sets it apart from other tools, positioning it as a critical infrastructure for the future of oncology. This funding rounds out a significant step toward realizing a more efficient and effective oncology landscape.